SMARCC1 and Miyoshi myopathy: The activity of each agent was shown to be pathway specific, as pomalidomide treatment of MM cells degraded its known protein targets, IKZF1 and IKZF3, without demethylating BAF155 (a known substrate of CARM1), and EZM2302 treatment led to a concentration-dependent decrease in methylated BAF155 without degrading IKZF1 or IKZF3 protein levels (Figure 1F).